ArticleRheumatology international2026
Muscle-dominant ANCA-associated vasculitis: a single-center cohort study.
Article in Rheumatology international, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Nephrotic range proteinuria and rapid progression to end-stage kidney disease in seronegative pauci-immune necrotizing glomerulonephritis masked by cutaneous lesions: a case-based review.Rheumatology international · 2026Review
- Defining muscle-dominant ANCA-associated vasculitis: the importance of systematic muscle MRI assessment.Rheumatology international · 2026Article
Corrections and comments
- Erratum issued
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
To investigate the clinical characteristics of muscle-dominant ANCA-associated vasculitis (muscle-dominant AAV) in a consecutive single-center cohort. We retrospectively analyzed consecutive patients newly diagnosed with microscopic polyangiitis (MPA) and granulomatosis with polyangiitis (GPA) at a single center. Cases with muscle-dominant AAV were defined as those with muscle involvement due to AAV in the absence of other organ manifestations, including glomerulonephritis, cutaneous vasculitis, vasculitic neuropathy, or alveolar hemorrhage. We compared the muscle-dominant AAV group with all remaining AAV patients, who served as the comparison group. Among 72 consecutive patients newly diagnosed with MPA or GPA, 8 (11%) were classified as having muscle-dominant AAV. All patients with muscle-dominant AAV (100%) were MPO-ANCA-positive. In all patients with muscle-dominant AAV, serum creatine kinase levels remained within the normal range despite MRI-confirmed muscle inflammation. Compared with the comparison group, the muscle-dominant AAV group had significantly higher rheumatoid factor (RF) levels. ROC analysis identified an exploratory RF cutoff value of 47.55 U/mL (AUC = 0.79). The prevalence of interstitial lung disease (ILD) tended to be more frequent in the muscle-dominant AAV group than in the comparison group (75 vs. 37.5%, p = 0.060). Muscle-dominant AAV was characterized by MPO-ANCA positivity, elevated RF levels, normal CK levels, and MRI-confirmed muscle involvement. ILD was often observed but did not reach statistical significance. These findings suggest a possible clinical pattern within AAV, which we tentatively refer to as the hypothesized IMARM pattern (ILD, MPO-ANCA, RF, myopathy).
Indexed as
Identifiers
42176044What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.